Aperio Clinical Outcomes Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aperio Clinical Outcomes's estimated annual revenue is currently $11.2M per year.(i)
  • Aperio Clinical Outcomes's estimated revenue per employee is $155,000

Employee Data

  • Aperio Clinical Outcomes has 72 Employees.(i)
  • Aperio Clinical Outcomes grew their employee count by -13% last year.

Aperio Clinical Outcomes's People

NameTitleEmail/Phone
1
Founder and CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
VP, Global Quality AssuranceReveal Email/Phone
4
VP Business DevelopmentReveal Email/Phone
5
VP, Business DevelopmentReveal Email/Phone
6
Associate Director Project ManagementReveal Email/Phone
7
Director, Budgets and ProposalsReveal Email/Phone
8
Senior Director, Data ManagementReveal Email/Phone
9
Director, eClinical TechnologiesReveal Email/Phone
10
Director, Clinical Research AnalyticsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M72-13%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
$0.9M11-39%N/AN/A
#6
$1.7M1110%N/AN/A
#7
$0.6M4-33%N/AN/A
#8
$4.8M31-6%N/AN/A
#9
$6.4M413%N/AN/A
#10
$4.2M27-18%N/AN/A
Add Company

What Is Aperio Clinical Outcomes?

Aperio Clinical Outcomes (formerly INNO Clinical Outcomes) provides full, customizable clinical research services across multiple therapeutic areas. More important, we offer what sponsors need most in today’s new world of healthcare: intelligence, honesty, and agility. We deliver comprehensive clinical research services with unmatched transparency. That’s why we chose the name Aperio — Latin for uncover or reveal. Aperio Clinical Outcomes. We make it clear.

keywords:N/A

N/A

Total Funding

72

Number of Employees

$11.2M

Revenue (est)

-13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.5M72-3%N/A
#2
$17.5M720%N/A
#3
$9.5M73-5%N/A
#4
$9.5M73N/AN/A
#5
$9.7M749%N/A